RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rakiem piersi rozsiającym się na inne organy
- •Przeprowadzona biopsja wątroby, płuc, opłucnej lub kości
- •Biopsja wykonana w okresie od stycznia 2005 do stycznia 2024
✗ Disqualifies
- •Brak dostępnych badań obrazowych (tomografia komputerowa i/lub PET-FDG) w ciągu trzech miesięcy przed biopsją
- •Nieznany status HER2
- •Biopsja z węzła chłonnego, tkanki miękkiej lub innego narządu wewnętrznego
Simplified criteria — AI translation
Trial details
- Last updated (source)
- June 22, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy
Trial contact
Claudio Vernieri, MD, PhD
Leonardo Provenzano, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.